May Khanna

List of Publications by Year
in descending order

67	2,331	147726 31	223716 46
papers	citations	h-index	g-index

73	73	73	2742
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca2+ channel complex. Nature Medicine, 2011, 17, 822-829.	15.2	200
2	Molecular chaperone Hsp90 stabilizes Pih1/Nop17 to maintain R2TP complex activity that regulates snoRNA accumulation. Journal of Cell Biology, 2008, 180, 563-578.	2.3	159
3	Discovery and characterization of small molecules that target the GTPase Ral. Nature, 2014, 515, 443-447.	13.7	126
4	Hierarchical CRMP2 posttranslational modifications control NaV1.7 function. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8443-E8452.	3.3	103
5	Structural Insights Into TDP-43 and Effects of Post-translational Modifications. Frontiers in Molecular Neuroscience, 2019, 12, 301.	1.4	86
6	Unique structural and stabilizing roles for the individual pseudouridine residues in the 1920 region of Escherichia coli 23S rRNA. Nucleic Acids Research, 2000, 28, 2075-2083.	6.5	83
7	A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain, 2015, 156, 1247-1264.	2.0	71
8	CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain, 2017, 158, 2301-2319.	2.0	67
9	Discovery of a Novel Class of Covalent Inhibitor for Aldehyde Dehydrogenases. Journal of Biological Chemistry, 2011, 286, 43486-43494.	1.6	65
10	Target-Specific Support Vector Machine Scoring in Structure-Based Virtual Screening: Computational Validation, In Vitro Testing in Kinases, and Effects on Lung Cancer Cell Proliferation. Journal of Chemical Information and Modeling, 2011, 51, 755-759.	2.5	59
11	(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. Pain, 2016, 157, 1448-1463.	2.0	54
12	(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. Molecular Neurobiology, 2016, 53, 1959-1976.	1.9	50
13	Inhibition of the Ubc9 E2 SUMO-conjugating enzymeâ€“CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain, 2018, 159, 2115-2127.	2.0	49
14	Targeting Multiple Conformations Leads to Small Molecule Inhibitors of the uPARÂ·uPA Proteinâ€“Protein Interaction That Block Cancer Cell Invasion. ACS Chemical Biology, 2011, 6, 1232-1243.	1.6	48
15	CRMP-2 Peptide Mediated Decrease of High and Low Voltage-Activated Calcium Channels, Attenuation of Nociceptor Excitability, and Anti-Nociception in a Model of AIDS Therapy-Induced Painful Peripheral Neuropathy. Molecular Pain, 2012, 8, 1744-8069-8-54.	1.0	48
16	Blocking CRMP2 SUMOylation reverses neuropathic pain. Molecular Psychiatry, 2018, 23, 2119-2121.	4.1	47
17	Small Molecule Targeting TDP-43â€™s RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS). ACS Chemical Biology, 2019, 14, 2006-2013.	1.6	45
18	Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injuryâ€“associated peripheral sensory neuropathy via block of N- and T-type calcium channels. Pain, 2019, 160, 117-135.	2.0	44

#	Article	IF	Citations
19	Small-molecule inhibition of the uPARÂ·uPA interaction: Synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorganic and Medicinal Chemistry, 2013, 21, 2145-2155.	1.4	43
20	Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channelâ€“CRMP-2 signaling complex. Channels, 2011, 5, 449-456.	1.5	40
21	Homologyâ€guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2â€derived peptides. British Journal of Pharmacology, 2018, 175, 2244-2260.	2.7	40
22	The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. Frontiers in Cellular Neuroscience, 2014, 8, 196.	1.8	38
23	Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. Frontiers in Cellular Neuroscience, 2015, 8, 471.	1.8	37
24	A peptide uncoupling CRMP-2 from the presynaptic Ca2+ channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy. Translational Neuroscience, 2012, 3, 1-8.	0.7	36
25	Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase. Molecular Cancer Therapeutics, 2011, 10, 626-636.	1.9	35
26	Thermodynamics of RNA hairpins containing single internal mismatches. Nucleic Acids Research, 1999, 27, 1118-1125.	6.5	34
27	Structural study of the H/ACA snoRNP components Nop10p and the 3' hairpin of U65 snoRNA. Rna, 2006, 12, 40-52.	1.6	34
28	A systematic characterization of Cwc21, the yeast ortholog of the human spliceosomal protein SRm300. Rna, 2009, 15, 2174-2185.	1.6	34
29	Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor. Bioorganic and Medicinal Chemistry, 2012, 20, 4760-4773.	1.4	34
30	A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels, 2017, 11, 316-328.	1.5	34
31	Discovery of novel regulators of aldehyde dehydrogenase isoenzymes. Chemico-Biological Interactions, 2011, 191, 153-158.	1.7	33
32	Virtual Screening Targeting the Urokinase Receptor, Biochemical and Cell-Based Studies, Synthesis, Pharmacokinetic Characterization, and Effect on Breast Tumor Metastasis. Journal of Medicinal Chemistry, 2011, 54, 7193-7205.	2.9	32
33	Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential. Pain, 2016, 157, 2124-2140.	2.0	30
34	Targeting the CaVÎ±â€“CaVÎ² interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. Pain, 2019, 160, 1644-1661.	2.0	30
35	Structural basis for 2â€²-phosphate incorporation into glycogen by glycogen synthase. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20976-20981.	3.3	29
36	Discovery and Characterization of 2,5-Substituted Benzoic Acid Dual Inhibitors of the Anti-apoptotic Mcl-1 and Bfl-1 Proteins. Journal of Medicinal Chemistry, 2020, 63, 2489-2510.	2.9	23

#	Article	IF	Citations
37	Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Science Translational Medicine, 2021, 13, eabh1314.	5.8	23
38	(â˜')-Hardwickiic Acid and Hautriwaic Acid Induce Antinociception via Blockade of Tetrodotoxin-Sensitive Voltage-Dependent Sodium Channels. ACS Chemical Neuroscience, 2019, 10, 1716-1728.	1.7	22
39	Mapping CRMP3 domains involved in dendrite morphogenesis and voltage-gated calcium channel regulation. Journal of Cell Science, 2013, 126, 4262-73.	1.2	21
40	The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels. ACS Chemical Neuroscience, 2019, 10, 4834-4846.	1.7	20
41	Relative Inhibitory Potency of Molinate and Metabolites with Aldehyde Dehydrogenase 2: Implications for the Mechanism of Enzyme Inhibition. Chemical Research in Toxicology, 2010, 23, 1843-1850.	1.7	19
42	An Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 Yields Neuroprotective Properties. ACS Chemical Biology, 2020, 15, 2854-2859.	1.6	19
43	Docking to Erlotinib Off-Targets Leads to Inhibitors of Lung Cancer Cell Proliferation with Suitable in Vitro Pharmacokinetics. ACS Medicinal Chemistry Letters, 2010, 1, 229-233.	1.3	18
44	Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels. Channels, 2018, 12, 219-227.	1.5	17
45	Animal Models of Neurodegenerative Disease: Recent Advances in Fly Highlight Innovative Approaches to Drug Discovery. Frontiers in Molecular Neuroscience, 2022, 15, 883358.	1.4	17
46	A novel variant in TAF1 affects gene expression and is associated with X-linked TAF1 intellectual disability syndrome. Neuronal Signaling, 2018, 2, NS20180141.	1.7	16
47	Synthesis of a 3-methyluridine phosphoramidite to investigate the role of methylation in a ribosomal RNA hairpin. Bioorganic and Medicinal Chemistry, 2002, 10, 325-332.	1.4	13
48	Reactions of platinum(II) complexes with a DNA hairpin, d(CGCGTTGTTCGCG): structural characterization and kinetic studies. Inorganica Chimica Acta, 2000, 297, 145-155.	1.2	12
49	Expression and purification of functional human glycogen synthase-1 (hGYS1) in insect cells. Protein Expression and Purification, 2013, 90, 78-83.	0.6	12
50	Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology. Scientific Reports, 2022, 12, 8140.	1.6	12
51	Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells. Stem Cell Reports, 2021, 16, 2459-2472.	2.3	11
52	In Silico Targeting of the Long Noncoding RNA MALAT1. ACS Medicinal Chemistry Letters, 2021, 12, 915-921.	1.3	10
53	A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B). ACS Chemical Biology, 2018, 13, 3000-3010.	1.6	9
54	Photoinduced cleavage by a rhodium complex at GÂ·U mismatches and exposed guanines in large and small RNAs. Biochimie, 2002, 84, 859-868.	1.3	7

#	Article	IF	Citations
55	RNA in control. Nature, 2007, 447, 391-393.	13.7	7
56	Direct targeting of TDP-43, from small molecules to biologics: the therapeutic landscape. RSC Chemical Biology, 2021, 2, 1158-1166.	2.0	6
57	The principles of tomorrow's university. F1000Research, 2018, 7, 1926.	0.8	6
58	1H, 15N and 13C backbone assignment of apo TDP-43 RNA recognition motifs. Biomolecular NMR Assignments, 2019, 13, 163-167.	0.4	3
59	Aptamers Targeting Hallmark Proteins of Neurodegeneration. Nucleic Acid Therapeutics, 2022, 32, 235-250.	2.0	3
60	Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief. Channels, 2019, 13, 498-504.	1.5	2
61	NMR Studies of Proteinâ€“RNA Interactions. Methods in Molecular Biology, 2012, 831, 197-218.	0.4	2
62	(399) A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses post-operative pain behaviors. Journal of Pain, 2015, 16, S75.	0.7	0
63	Remodeling the interactions between TDP43 and RNA for development of therapeutics for ALS. FASEB Journal, 2019, 33, 670.1.	0.2	0
64	Abstract LB-226: Discovery of small molecule Mcl-1 and Bfl-1 inhibitors. , 2020, , .		0
65	Modeling of Pontocerebellar Hypoplasia Type 1B and Chemical Mimicry in Patient-Derived Neural Stem Cells. SSRN Electronic Journal, 0, , .	0.4	0
66	Chemical Probes to Control RNA Function. Chemical Biology, 2020, , 214-246.	0.1	0
67	Small Molecules Targeting RIPK3/MLKL Interactions Disrupt Necroptosis. SSRN Electronic Journal, 0, , .	0.4	0